Allogeneic Stem Cell Transplantation Market Segmentation And Share Contributing
 |
| Allogeneic Stem Cell Transplantation Market |
The Allogeneic Stem Cell Transplantation Market is
estimated to be valued at US$ 3.9
Billion In 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 - 2030, as highlighted
in a new report published by Coherent Market Insights.
Market Overview:
Allogeneic stem cell transplantation involves replacing a patient's
blood-forming system with stem cells from a matched donor. It is primarily used
to treat various types of blood cancer like leukemia, myeloma, and lymphoma.
Allogeneic stem cell transplantation provides patients with a new set of stem
cells which helps in renewing their blood and immune systems that the high-dose
chemotherapy and radiation destroy to treat cancer.
Market key trends:
The Allogeneic Stem Cell Transplantation Market is expected to witness high
growth owing to increasing prevalence of blood cancer worldwide. According to
the American Cancer Society, about 191,000 cases of leukemia, lymphoma, and
myeloma are expected to be diagnosed in the United States in 2023. Allogeneic
stem cell transplantation serves as one of the most effective treatment options
for these types of blood cancer. Additionally, ongoing research and clinical
trials focusing on developing novel techniques for allogeneic transplantation
are further supporting the market growth. Growing healthcare expenditure and
rising awareness about stem cells therapies are some other factors expected to
propel the demand for allogeneic stem cell transplantation over the forecast
period.
Porter's Analysis
Threat of new entrants: Low start-up costs and intellectual property
protections limit new competitors in this Allogeneic
Stem Cell Transplantation Market. Bargaining power of buyers:
Individual patients have little bargaining power, while larger healthcare
providers can negotiate with suppliers on pricing and contracts. Bargaining
power of suppliers: A few major companies dominate the supply chain, giving
them significant influence over price and product selection. Threat of new
substitutes: Cell therapies and gene therapies may emerge as alternatives but
require extensive R&D and face regulatory hurdles. Competitive rivalry:
Strong competition exists among major suppliers to develop new products and
target new indications.
SWOT Analysis
Strengths: Strong R&D pipelines focused on new indications and product
enhancements. Acquisitions expand technology and service portfolios.
Weaknesses: High costs and limited insurance coverage create financial
barriers. Cell sourcing and manufacturing challenges lower supply reliability.
Opportunities: Expanding approvals into new disease areas drive market growth.
Partnerships improve access and distribution infrastructure. Threats: Strict
regulations slow clinical trials and product approvals. Reimbursement policies
impact adoption rates.
Key Takeaways
The global allogeneic stem cell transplantation market is expected to witness
high growth, exhibiting a CAGR of 7.9%
over the forecast period, due to increasing prevalence of leukemia, lymphoma
and other cancers. The US market currently dominates due to favorable
regulatory environment and reimbursement policies but the Asia Pacific region
is poised to grow the fastest between 2023 - 2030 with countries like China,
Japan and South Korea emerging as major hubs for stem cell research and
clinical trials.
Regional analysis: The North America region currently holds the largest share
of the allogeneic stem cell transplantation market due to growing geriatric
population and rising incidences of cancer. However, Asia Pacific is expected
to witness the highest CAGR over the forecast period due to increasing
healthcare expenditure, growing medical tourism industry and rising initiatives
by market players in countries like China, Japan and India.
Key players: Key players operating in the allogeneic stem cell transplantation
market are Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc.,
MEDIPOST Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma
Inc., Cellular Biomedicine Group, Inc., Biosolution Co., Ltd., StemCell
Technologies Inc., Caladrius Biosciences, Inc., TiGenix N.V., ViaCord, Vericel
Corporation, Regen Biopharma Inc., Gamida Cell Ltd., Histogenics Corporation,
BrainStorm Cell Therapeutics Inc., Lineage Cell Therapeutics, Inc.
Comments
Post a Comment